Globus Medical initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Craig Bijou started Globus Medical with an Overweight rating and $65 price target. The analyst sees several sales growth drivers for the company, including a U.S. core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform.
Thursday, May 31, 2018
K2M started at buy by Cantor
K2M Group initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Craig Bijou started K2M Group with an Overweight rating and $28 price target. The company’s outperformance in the U.S. market over the last two years has been underappreciated, Bijou tells investors in a research note. He sees the U.S. momentum continuing in 2018 and beyond, driven by innovative new product launches and sales rep hires.
Orthofix started at buy by Cantor
Orthofix initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Craig Bijou started Orthofix with an Overweight rating and $62 price target. The analyst believes the recent share pullback provides a good entry point, especially ahead of more details on the benefit of re-domiciling to the U.S.
Tonix says Phase 2 study shows Tonmya reduces PTSD symptoms
Tonix Pharmaceuticals presented data from the Phase 2 AtEase study of Tonmya for the treatment posttraumatic stress disorder. The presentation focused on the rationale for including suicidal individuals in the clinical trial of a treatment for PTSD. “There are several examples in major psychiatric disorders in which pharmacological treatment of the underlying disorder may decrease suicidal behaviors,” said Gregory Sullivan, M.D., Chief Medical Officer of Tonix. “Individuals with military-related PTSD have an elevated risk for suicidal behaviors, and it was hypothesized that addressing underlying PTSD with Tonmya might have an impact on reducing suicidal behaviors. Suicidal individuals were included in the AtEase study as it provided for a more representative sample of the condition for evaluating the efficacy Tonmya 2.8 mg and 5.6 mg as a potential treatment for military-related PTSD.” “Taken nightly at bedtime and absorbed by a sublingual route, Tonmya is believed to reduce PTSD symptoms through improvement in sleep quality, potentially also addressing suicidal behaviors via upstream effects on sleep improvement,” Dr. Sullivan continued “While rates of suicidal ideation and behaviors were not high enough to allow meaningful statistical analyses in AtEase, these data, combined with other datasets acquired by similar methodology, may provide important new information and insights leading to better prediction of, and interventions to prevent, suicides in PTSD.”
J&J Esketamine Shows Promise in Depression Clinical Trials
The Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.
The findings were presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) held in Miami Beach, Florida. The first trial evaluated relapse prevention in adults with treatment-resistant depression. The data showed that continuing treatment with esketamine nasal spray with an oral antidepressant beyond 16 weeks had clinically meaningful and statistically significant superiority to just an antidepressant and placebo in delaying time to relapse of depression symptoms.
The trial also showed that patients receiving the drug with an oral antidepressant had a 51 percent less risk of relapse than patients in the antidepressant-plus-placebo group.
The second study was an open-label trial to assess the long-term safety and efficacy of esketamine nasal spray for up to a year. There were no new safety signals and it was similar to those seen in previously completed short-term Phase II and III trials. From an efficacy standpoint, it also showed that esketamine nasal spray plus an oral antidepressant gave sustained improvement in depressive symptoms up to 52 weeks.
“At least 300 million people worldwide live with treatment-resistant depression, and it is important we continue to study and report the results of studies such as these two,” said Maurizio Fava, executive vice chair of the Massachusetts General Hospital (MGH) Department of Psychiatry and executive director of the MGH Clinical Trials Network and Institute (CTNI), in a statement. “The first study shows that esketamine may be beneficial in terms of extending time to relapse for patients with treatment-resistant depression, and the second provides insights related to its safety over the long-term in this patient population.”
Safety results were consistent with the previous Phase II and III trials. The most comment adverse events were metallic taste (27%), vertigo (25%), dissociation (22.4%), drowsiness (21.1%), dizziness (20.4%), headache (17.8%), nausea (16.4%), blurred vision (15.8%) and diminished sense of touch or sensation (13.2%). Most adverse events were seen on the first day of dosing and generally resolved the same day.
The company also stated, “Fifty-five (6.9%) patients experienced 68 serious treatment-emergent adverse events. Of these, five serious treatment-emergent adverse events from four subjects were assessed by the investigator as esketamine nasal spray-related. There were two deaths which the investigator determined to be unrelated to esketamine nasal spray or oral antidepressant use. Laboratory tests, physical examination, and nasal tolerability revealed no trends of clinical concern in patients treated with esketamine nasal spray for up to 52 weeks. No clinically meaningful changes in cognition were found. No cases of interstitial or ulcerative cystitis were reported.”
Esketamine is a low dose of ketamine, a drug of abuse sometimes called “Special K” and used as a horse tranquilizer. The five serious adverse events were apparently depression, delirium, anxiety and delusion, suicidal ideation and suicide attempt.
If the drug were to be approved by the Food and Drug Administration (FDA), it would be the first new pharmacotherapeutic approach to treating refractory major depressive disorder in 50 years.
Antidepressants are typically selective serotonin reuptake inhibitors (SSRIs), such as Prozac and Zoloft, or serotonin-norepinephrine reuptake inhibitors (SNRIs), likes Pristiq or Efexor. They both affect serotonin neutrotransmitters by blocking serotonin reuptake and locking it in the gap between neurons for longer than usual.
Esketamine falls into a newer class of antidepressants, and target NMDA receptors, which regulate the concentrations of the glutamate neurotransmitter in the brain. Another product with a similar method of action under development is ALKS5461, an opioid, by Alkermes That drug is currently under review by the FDA and has a target action date of January 31, 2019.
Uncovering the role of the ApoE gene in Alzheimer’s
A study conducted at the Massachusetts Institute of Technology has identified why the ApoE4 gene increases the risk of developing Alzheimer’s disease.
Image Credit: Andrii Vodolazhskyi / Shutterstock
Apolipoprotein E (ApoE) is a class of proteins involved in the metabolism of fats, including cholesterol. ApoE surrounds fats to form lipoproteins, which facilitates the transport of fats in the bloodstream. There are three variants of the gene encoding ApoE: ApoE2, ApoE3 and ApoE4.
ApoE3 is the most common variant, being present in 78% of the population, and does not appear to influence the risk of developing Alzheimer’s disease.
However, presence of the ApoE4 gene variant, which occurs in approximately 14% of people, increases the risk for Alzheimer’s disease and lowers the age of onset of the disease. In contrast, the rarest variant ApoE2 reduces the risk of developing Alzheimer’s disease by up to 40%.
It has long been known that the distribution of ApoE gene variants differs considerably among patients with late-onset Alzheimer’s disease (the most common form of the disease).
The proportion of individuals in this subpopulation carrying the ApoE4 is almost three times as high as the general population, whereas the prevalence of the protective ApoE2 gene variant is halved.
Despite this apparent link, it was not understood why ApoE4 increases the risk of developing Alzheimer’s disease.
To establish why variants of the same gene can have such different impacts on Alzheimer’s disease risk, neuroscientists conducted a comprehensive study of ApoE4 and ApoE3 in brain cells.
They discovered that the ApoE4 gene variant promoted the accumulation of the beta amyloid proteins that comprise the characteristic plaques that form in the brains of patients with Alzheimer’s disease.
ApoE4 influences every cell type that we studied, to facilitate the development of Alzheimer’s pathology, especially amyloid accumulation…ApoE4 is by far the most significant risk gene for late-onset, sporadic Alzheimer’s disease”.Li-Huei Tsai, Senior Author
The study also demonstrated that the presence of ApoE3 and ApoE4 affected the expression of hundreds of other genes and these effects were greatest in microglial cells, which are responsible for the removal of foreign matter, including amyloid proteins and bacteria.
Microglia functioned at a much slower rate when containing the ApoE4 gene variant compared with ApoE3. In addition, neurons with ApoE4 secreted higher levels of amyloid protein than neurons with ApoE3.
Furthermore, the researchers successfully reversed these effects in brain cells containing the ApoE4 gene by using gene editing technology to convert the gene into the ApoE3 variant.
The results of this study this indicate that in Alzheimer’s disease brain cells produce more amyloid protein, whilst their ability to remove it is dramatically impaired and that these effects are reversible.
It is hoped that the gene expression profiling performed will reveal potential targets for therapeutic intervention. There is the possibility that Alzheimer’s disease risk and symptoms could be reduced by converting ApoE4 to ApoE3 in individuals with high ApoE4 expression.
Weight gain may be the result of inefficient fat metabolism
Researchers from the Karolinska Institutet have shown that protracted weight gain can, in some cases, be attributed to a reduced ability to metabolise fat.
The team says certain people may need more intensive lifestyle changes if they are to decrease their risk of becoming overweight or developing type 2 diabetes.
We’ve suspected the presence of physiological mechanisms in fatty tissue that cause some people to become overweight and others not, despite similarities in lifestyle, and now we’ve found one.”Professor Mikael Rydén, Study Author
Rydén and colleagues are now working to develop a way of measuring the body’s ability to break down fat.
For the study, the researchers analysed subcutaneous fat samples taken from the abdomens of women before and after a follow-up period of approximately a decade.
As reported in the journal Cell Metabolism, they found that the ability of the fat cells to release fatty acids in the first tissue sample could be used to predict which women would have developed type 2 diabetes at the end of the study.
This fatty acid release, referred to as lipolysis, is a process the body uses to provide an energy source in muscles.
Researchers differentiate between two types of lipolysis – basal lipolysis, which is ongoing, and hormone-stimulated lipolysis, which occurs in response to an increased need for energy.
Rydén and team found that the fat cells from women who later became overweight showed a high basal, but low hormone-stimulated lipolysis that increased the risk of weight gain and type 2 diabetes by 3 to 6 times.
“It’s a bit like a car that’s at high revs but that’s lost its ability to get into gear when it needs to. The end result is that the fat cells eventually take up more fat than they can get rid of,” explains Rydén.
He says the results now need to be corroborated in larger studies and for men.
We hope to develop a clinically expedient way of identifying individuals at risk of developing overweight and type 2 diabetes, who might need more intensive lifestyle intervention than others to stay healthy.”Professor Mikael Rydén
Subscribe to:
Posts (Atom)